Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Slide-DNA-Sequencing for Copy Number Mapping Global Market Report 2026 | Capitalize on AI and Spatial Genomics with Illumina, 10x Genomics and BGI Genomics

globenewswire.com
ILMN Illumina is mentioned as a key company in the growing slide-DNA sequencing market, which is benefiting from advances in genomic research, precision medicine, and AI. The company's technologies are crucial for high-resolution DNA mapping and spatial genomics analytics. TXG 10x Genomics is highlighted as a key player in the expanding slide-DNA sequencing market. The company's technologies are relevant to trends like spatial genomics analytics and single-cell sequencing, which are driving market growth.

Slide-DNA-Sequencing for Copy Number Mapping Global Market Report 2026 | Capitalize on AI and Spatial Genomics with Illumina, 10x Genomics and BGI Genomics Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Slide-Deoxyribonucleic Acid (DNA)-Sequencing for Copy Number Mapping Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global slide-deoxyribonucleic acid (DNA) sequencing for copy number mapping market is experiencing rapid growth, supported by advances in genomic research, precision medicine, high-throughput imaging, and molecular diagnostics. The market is projected to increase from $0.38 billion in 2025 to $0.43 billion in 2026, representing a compound annual growth rate (CAGR) of 14.6%.

Historical market expansion has been driven by improvements in fluorescent labeling techniques, wider adoption of optical mapping sequencing, increased cancer genomics research, continued investigation of genetic diseases, and the expansion of academic genomics infrastructure. These developments have improved the ability of researchers and healthcare professionals to identify genomic duplications, deletions, amplifications, and other copy number variations with greater resolution and accuracy.

The slide-DNA sequencing for copy number mapping market is forecast to reach $0.75 billion by 2030, expanding at a CAGR of 14.8%. Growth during the forecast period is expected to be supported by artificial intelligence-driven variant calling, demand for high-throughput imaging, adoption of single-molecule sequencing, personalized medicine applications, and the establishment of genomic laboratories in emerging markets.

Key slide-DNA sequencing market trends include high-resolution DNA mapping, integration with single-cell sequencing, automated slide processing, spatial genomics analytics, and predictive modeling of genomic variation. The convergence of sequencing, imaging, automation, and advanced analytics is expected to improve workflow efficiency while enabling more detailed analysis of genetic changes within tissue samples.

Growing demand for precision medicine is a major factor accelerating market development. Detailed copy number mapping helps identify genomic variations that can inform patient-specific diagnosis, treatment selection, risk assessment, and clinical decision-making. As healthcare systems increase their focus on targeted therapies, genomic technologies capable of producing high-resolution molecular insights are becoming more important in research and clinical settings.

Recent growth in personalized therapies highlights this shift. According to the Personalized Medicine Coalition, the US Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases in 2023, compared with six approvals in 2022. The increase demonstrates the expanding role of genomic information in therapeutic development and supports demand for advanced sequencing and copy number analysis technologies.

The increasing prevalence and detection of genetic disorders are also contributing to growth in the slide-DNA sequencing for copy number mapping market. Advanced diagnostic capabilities are enabling earlier identification of inherited conditions and genomic abnormalities. Copy number mapping supports the accurate detection of duplications and deletions associated with disease, helping healthcare professionals strengthen diagnostic assessments, develop personalized treatment strategies, and monitor disease progression.

For example, the UK National Health Service reported in May 2024 that approximately 17,000 people were living with sickle cell disease in the country, with around 250 new cases diagnosed annually. The continued burden of inherited diseases reinforces the need for genomic research, improved screening capabilities, and diagnostic platforms that can identify clinically relevant DNA variations.

Rising healthcare expenditure is further supporting the adoption of slide-DNA sequencing technologies. Greater investment in genomic infrastructure, specialized laboratory equipment, advanced reagents, bioinformatics platforms, and skilled personnel is helping expand sequencing capacity across clinical and research environments. This funding also supports diagnostic initiatives and improves access to personalized approaches for managing cancer, rare diseases, and inherited disorders.

According to the UK Office for National Statistics, total healthcare expenditure increased by 5.6% in nominal terms in 2023, representing a 0.9% increase compared with 2022. Continued healthcare investment is expected to facilitate broader adoption of genomic technologies and support the development of more efficient sequencing, imaging, and analytical workflows.

North America was the largest region in the slide-DNA sequencing for copy number mapping market in 2025, reflecting its established genomics infrastructure, extensive research activity, and adoption of advanced diagnostic technologies. Asia-Pacific is expected to be the fastest-growing region during the forecast period as genomic laboratories expand and investment in precision medicine increases. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries assessed include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.

Markets Covered:

Subsegments:

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes:

Companies Featured

The companies featured in this Slide-Deoxyribonucleic Acid (DNA)-Sequencing for Copy Number Mapping market report include:

For more information about this report visit https://www.researchandmarkets.com/r/kgnib7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.